抗感染药物的药物经济学研究现状和展望

The current status and future prospects of pharmacoeconomic study on anti-infective drugs

目的了解药物经济学近年来在抗感染领域发展现状。方法以“感染”、“药物经济学”、“infection”和“cost”为主题词检索2013~2023年发表在万方医学网、CNKI和Pubmed上的抗感染药物经济学文献进行统计分析,对文献资料“研究设计”和“评价方案”等进行统计分析。结果共检索到236篇有效文献,以回顾性队列研究最多,药物比较设计方案众多,不同药物间的比较占多数,其中以两种药物比较最多。对感染类型的研究涉及众多类型,以下呼吸道感染为主,其中肺部感染和社区获得性肺炎为主。抗菌药物间的比较以同类药物为主,包括头孢菌素类、氟喹诺酮类、碳青霉烯类、抗厌氧菌等。结论应参照《中国药物经济学评价指南(2020版)》,丰富药物经济学研究方法和内容,促进研究结果产生实效,降低感染疾病的治疗成本和促进抗菌药物的临床合理应用。

Objective To determine the development status of pharmacoeconomics in anti-infection field in recent years.Methods Retrieved“infection”,“Pharmacoeconomic”,“infection”and“cost”from WanFang,CNKI database and Pubmed between 2013 and 2023.Study design,and program evaluation were analyzed.Results A total of 236 valid articles were retrieved,most of which were retrospective cohort studies.There were many drug comparison designs,and most of them were comparisons between different drugs.Among them,two drugs were compared most.Research on infection types encompasses various categories,with a primary focus on lower respiratory tract infections such as pulmonary infections and community-acquired pneumonia.The comparison among antibiotics primarily focused on the same category of medications,encompassing cephalosporins,fluoroquinolones,carbapenems,anti-anaerobes,etc.Conclusion It is imperative to consult the“CHINA GUIDELINES FOR PHARMACOECONOMIC EVALUATIONS(2020 edition)”in order to enhance the methodologies and content of pharmacoeconomic research,bolster the efficacy of research findings,reduce the cost of treating infectious diseases,and foster judicious clinical application of antibiotics.